Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
$9.02
-4.0%
$11.24
$6.36
$47.45
$1.03B1.081.91 million shs1.58 million shs
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$9.15
-2.9%
$8.95
$6.50
$18.98
$968.89M0.8885,669 shs437,095 shs
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
$16.29
-3.6%
$15.73
$10.91
$40.26
$981.96M2.68574,985 shs331,568 shs
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
$6.26
-1.9%
$7.51
$6.23
$21.79
$237.57M-0.11134,463 shs118,687 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
+0.75%+6.82%-13.44%+15.06%-77.34%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
+1.95%-0.66%+8.16%+19.75%-39.01%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
+4.26%+5.83%+11.26%+33.31%-46.21%
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
0.00%-5.62%-11.51%-21.53%-62.73%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
3.8979 of 5 stars
4.53.00.00.03.04.20.0
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
2.3549 of 5 stars
4.41.00.00.01.61.70.0
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
1.9456 of 5 stars
3.60.00.00.01.62.50.6
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
3.3411 of 5 stars
3.61.00.00.03.02.51.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
3.00
Buy$40.63350.39% Upside
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
2.89
Moderate Buy$21.29132.63% Upside
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
3.29
Buy$53.40227.81% Upside
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
3.25
Buy$25.67310.01% Upside

Current Analyst Ratings Breakdown

Latest TRDA, RCUS, DYN, and SYRE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/15/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$10.00 ➝ $9.00
7/11/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
6/26/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$30.00
6/25/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/24/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform$13.00
6/18/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00
6/18/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$46.00 ➝ $32.00
6/17/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00
6/11/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$37.00
6/2/2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$60.00 ➝ $34.00
5/20/2025
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/A$6.19 per shareN/A
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$258M3.76N/AN/A$5.30 per share1.73
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
$890K1,103.33N/AN/A$7.04 per share2.31
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
$210.78M1.13$1.56 per share4.02$11.46 per share0.55
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$317.42M-$3.59N/AN/AN/AN/A-52.83%-48.84%8/11/2025 (Estimated)
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-$283M-$4.19N/AN/AN/A-258.94%-70.58%-32.97%8/4/2025 (Estimated)
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-$208.02M-$3.77N/AN/AN/AN/A-77.46%-41.06%8/6/2025 (Estimated)
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
$65.63M$0.817.73N/AN/A14.39%5.84%4.61%8/12/2025 (Estimated)

Latest TRDA, RCUS, DYN, and SYRE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-$1.14N/AN/AN/AN/AN/A
8/12/2025Q2 2025
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
-$0.86N/AN/AN/A$8.17 millionN/A
8/11/2025Q2 2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$0.99N/AN/AN/AN/AN/A
8/6/2025Q2 2025
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-$0.68N/AN/AN/AN/AN/A
5/8/2025Q1 2025
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$0.88-$1.05-$0.17-$1.05N/AN/A
5/8/2025Q1 2025
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-$0.76-$0.74+$0.02-$0.74N/AN/A
5/8/2025Q1 2025
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
-$0.78-$0.42+$0.36-$0.42$10.98 million$8.75 million
5/6/2025Q1 2025
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-$1.02-$1.14-$0.12-$1.14$38.61 million$28.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/AN/A
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
N/AN/AN/AN/AN/A
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
N/AN/AN/AN/AN/A
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/A
20.35
20.35
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
0.09
5.37
5.37
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
N/A
8.06
8.06
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
N/A
21.88
21.88

Institutional Ownership

CompanyInstitutional Ownership
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
96.68%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
92.89%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
80.39%
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
86.39%

Insider Ownership

CompanyInsider Ownership
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
14.14%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
9.60%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
15.43%
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
8.11%
CompanyEmployeesShares OutstandingFree FloatOptionable
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
100113.67 million97.59 millionOptionable
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
500105.89 million95.72 millionOptionable
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
7360.28 million50.98 millionOptionable
Entrada Therapeutics, Inc. stock logo
TRDA
Entrada Therapeutics
11037.95 million34.88 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Dyne Therapeutics stock logo

Dyne Therapeutics NASDAQ:DYN

$9.02 -0.38 (-4.04%)
Closing price 04:00 PM Eastern
Extended Trading
$9.16 +0.15 (+1.61%)
As of 04:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Arcus Biosciences stock logo

Arcus Biosciences NYSE:RCUS

$9.15 -0.27 (-2.87%)
Closing price 03:59 PM Eastern
Extended Trading
$9.14 -0.01 (-0.05%)
As of 04:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Spyre Therapeutics stock logo

Spyre Therapeutics NASDAQ:SYRE

$16.29 -0.60 (-3.55%)
Closing price 04:00 PM Eastern
Extended Trading
$16.44 +0.15 (+0.92%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

Entrada Therapeutics stock logo

Entrada Therapeutics NASDAQ:TRDA

$6.26 -0.12 (-1.88%)
Closing price 04:00 PM Eastern
Extended Trading
$6.27 +0.01 (+0.16%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.